CHI Podcasts

For decades, high-performance computing (HPC) has played a crucial role in advancing healthcare. Enabled by techniques like next-generation sequencing (NGS), modern computer systems have helped us understand the biology of disease and helped facilitate the development of newer more effective drugs. While once deployed mainly in research, today HPC is edging ever closer to front-line clinical care supporting advanced diagnostics, genetic counseling, and personalized medicine.

While core bioinformatics applications aren’t going anywhere, modern medicine is increasingly a big data problem as well. Determining the optimal treatment depends on collaboration, the fusion of genetic data with other rich datasets like MRIs, ultrasound images, and population level studies. Increasingly analytics and AI techniques like machine learning are helping healthcare providers sift through massive amounts of data to make better decisions for patients more quickly and efficiently.

For IT organizations, providing a foundation to support this rapid innovation has been challenging. With the need for increasingly specialized hardware, new application frameworks, cost challenges, and the need to share data as never before, institutions are increasingly embracing cloud computing. Univa has played a key role in helping life sciences companies manage diverse workloads on HPC clusters both on-premises and in the cloud. In this Podcast, Univa will discuss how workloads are evolving, share some of the pressures faced by their life-sciences customers, and discuss practical approaches to modernizing IT environments to support the increased variety of applications in the life sciences software ecosystem.

Dr. Bradley Perkins develops a digital platform that can estimate personalized ten year mortality risk. In this podcast, he shares with us what this platform is and how it works to protect and improve the health of individuals and families. In the era of personalized medicine, Dr. Perkins explains what the necessary steps to bring this platform to the general public, gives us other personalized medicine examples and how it will affect the cost of medical care.

For more information, please visit http://www.TriConference.com/Precision-Medicine

A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic Medicine

A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans Affairs

A re-upload of a podcast with Marc Berger, M.D., Vice President, Real World Data & Analytics, Pfizer

Prof. Dai Fukumura gives a preview of his talk, shares some challenges of reprograming tumor microenvironment and what he would like to see more in this field.

For more information, please visit http://www.DiscoveryOnTarget.com/Tumor-Myeloid-Cells/

Dr. Jeffrey Miller shares his experience in NK cell field in the last 20 years, comparing NK cells with T cells and their cost differences along with giving some advice to the young scientists in the field.

For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/

Dr. James Trager shares a preview of his talk at the NK cell-based cancer immunotherapy meeting in Boston, discusses his next step in research and the vision of Nkarta in NK cell therapy development and what he’s looking forward to at this meeting such as the topics of inhibition of MIC protein shedding and NK cell metabolism.

For more information, please visit http://www.DiscoveryOnTarget.com/NK-Cell-Based-Cancer-Immunotherapy/

Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at PEGS Europe, 12-16 November 2018 in Lisbon, Portugal.

For more information, please visit http://www.PEGSummitEurope.com/Optimising-Protein-Expression

Topics Questions Include:

Let's talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade?

What potential solutions seem promising for some … challenges?

Are there promising glimpses into using transient protein gene expression for clinical use today?

You'll be discussing “Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What's the main theme you'd like to convey to your audience of protein engineers and researchers?

Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress.

For more information, please visit http://www.BispecificAntibodyCongress.com/Bispecific-Antibody-Clinical-Relevance